| scholarly article | Q13442814 |
| P2093 | author name string | Fennerty MB | |
| Hwang C | |||
| Sostek M | |||
| Johanson JF | |||
| P2860 | cites work | Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis | Q43939369 |
| Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms | Q45045271 | ||
| Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology | Q33864468 | ||
| Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole | Q39461816 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | esomeprazole | Q553223 |
| P304 | page(s) | 455-463 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis | |
| P478 | volume | 21 |
| Q42662159 | A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease |
| Q83208440 | A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis |
| Q37160360 | A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). |
| Q51609254 | An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. |
| Q42283418 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
| Q46753176 | Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease |
| Q30431802 | Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis |
| Q36230670 | Developments in the inhibition of gastric acid secretion |
| Q37802963 | Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system |
| Q36024697 | Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole |
| Q39360558 | Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study |
| Q33601940 | Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study |
| Q30458922 | Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials |
| Q37032564 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults |
| Q37755220 | Esomeprazole: potent acid suppression in the treatment of acid-related disorders |
| Q48458474 | Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con. |
| Q34775943 | Guide to the use of proton pump inhibitors in adult patients |
| Q37762466 | Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus |
| Q80154601 | Heartburn severity does not predict disease severity in patients with erosive esophagitis |
| Q44066735 | Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. |
| Q37808356 | Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole |
| Q41343848 | Management of reflux esophagitis: does the choice of proton pump inhibitor matter? |
| Q37260543 | Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole |
| Q43854731 | Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials |
| Q39252347 | PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis |
| Q89421768 | Patient acceptability and experiences of therapeutic switching of proton pump inhibitors within the National Preferred Drugs initiative in Ireland |
| Q38229080 | Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease |
| Q34756783 | Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan |
| Q44482108 | Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors |
| Q37238180 | Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis |
| Q38415822 | Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects |
| Q36265354 | Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan |
| Q36478873 | Review article: acid-related disease--what are the unmet clinical needs? |
| Q36319521 | Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. |
| Q34558655 | Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. |
| Q37552951 | The pharmacology of esomeprazole and its role in gastric acid related diseases |
| Q35209935 | The value of branded proton pump inhibitors: formulary considerations. |
Search more.